Germany's Tubulis Raises €308m for ADC Pipeline

Germany's Tubulis raises €308m for ADC pipeline

Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer

German biotech Tubulis raises $358 million to advance cancer treatments

The company, which is developing antibody-drug conjugates, will use the funding to push its lead drug candidate into trials in additional types of cancer.

Cancer drug startup Tubulis raises $361 million for ADCs

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer drug that’s currently in early-stage testing.

Tubulis secures €308m in record-breaking Series C financing   - European Biotechnology Magazine

Munich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The attractivity lays in the technologyplatform of linking the payload. The post Tubulis secures €308m in record-breaking Series C financing   ap…

Tubulis snags $361M for clinical-stage ADCs

Tubulis is headed to one of the leading cancer R&D conferences with the fifth-largest private biotech fundraise of 2025. The Munich-based ADC biotech will present its first clinical data at the European Society for Medical ...